Read by QxMD icon Read


Jose Carlos De Miguel Bouzas, Eva Castro Tubío, Leticia Herrero Poch, Carlos González Portela
No abstract text is available yet for this article.
September 2016: Farmacia Hospitalaria
Gillian M Keating
A fixed-dose tablet comprising the NS5A inhibitor ombitasvir, the NS3/4A inhibitor paritaprevir and ritonavir (ombitasvir/paritaprevir/ritonavir) (Technivie(®), Viekirax(®)) is available for use, in combination with ribavirin, for the treatment of chronic hepatitis C virus (HCV) genotype 4 infection. High sustained virological response rates at 12 weeks post-treatment (SVR12) were achieved in treatment-naive or -experienced patients with chronic HCV genotype 4 infection, including patients without cirrhosis who received ombitasvir plus paritaprevir and ritonavir in combination with ribavirin for 12 weeks (SVR12 100 %) (PEARL-I trial), patients with compensated cirrhosis who received ombitasvir/paritaprevir/ritonavir plus ribavirin for 12 or 16 weeks (SVR12 97 and 98 %) (AGATE-I trial), or Egyptian patients without cirrhosis who received ombitasvir/paritaprevir/ritonavir plus ribavirin for 12 weeks (SVR12 94 %) or with compensated cirrhosis who received ombitasvir/paritaprevir/ritonavir plus ribavirin for 12 or 24 weeks (SVR12 97 and 93 %) (AGATE-II trial)...
August 2016: Drugs
(no author information available yet)
In patients with HCV genotype 4 (HCV-4) infection, initial assessment of ombitasvir + ritonavir-boosted paritaprevir+ ribavirin combination therapy for 12 weeks is based primarily on an unblinded trial in 135 patients without cirrhosis. Virological efficacy was achieved in every case. In early 2016, this combination is the peginterferon alfa-sparing antiviral regimen with the least weak evidence of virological efficacy in HCV-4 infection. In HCV-1 infection, clinical trials of this regimen combined with dasabuvir showed no improvement over the ledipasvir + sofosbuvir combination...
May 2016: Prescrire International
(no author information available yet)
In late 2015, the first-choice treatment for patients with chronic hepatitis C due to a genotype 1 virus (HCV-1) was the combination of ledipasvir (an NS5A protein inhibitor) + sofosbuvir (a nucleotide inhibitor of NS5B RNA polymerase), despite major uncertainties regarding its adverse effects. This combination is almost always virologically effective. Dasabuvir is a non-nucleoside inhibitor of the viral RNA polymerase NS5B. It is authorised in the EU for the treatment of patients with chronic hepatitis C due to HCV-1, usually combined with the fixed-dose combination (Viekirax) of ombitasvir (an HCV NS5A protein inhibitor) + paritaprevir (an HCV protease inhibitor) + ritonavir (to enhance paritaprevir bioavailability)...
May 2016: Prescrire International
Xingquan Zhang
Unlike human immunodeficiency virus (HIV) and hepatitis B virus (HBV), hepatitis C virus (HCV) infection is a curable disease. Current direct antiviral agent (DAA) targets are focused on HCV NS3/4A protein (protease), NS5B protein (polymerase) and NS5A protein. The first generation of DAAs includes boceprevir and telaprevir, which are protease inhibitors and were approved for clinical use in 2011. The cure rate for genotype 1 patients increased from 45% to 70% when boceprevir or telaprevir was added to standard PEG-IFN/ribavirin...
January 2016: Acta Pharmaceutica Sinica. B
Emma D Deeks
A fixed-dose tablet comprising ombitasvir (an NS5A replication complex inhibitor), paritaprevir (an NS3/4A protease inhibitor) and ritonavir (a cytochrome P450 inhibitor) taken in combination with dasabuvir (an NS5B polymerase inhibitor) is indicated for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection in several countries, including the USA (copackaged as Viekira Pak(™)) and those of the EU (Viekirax(®) and Exviera(®)). In phase II and III trials, this interferon-free regimen, taken ± ribavirin, provided high rates of sustained virological response 12 weeks post-treatment in adults with chronic HCV genotype 1a or 1b infection, including those with compensated cirrhosis, liver transplants or HIV-1 co-infection...
June 2015: Drugs
Massimo Colombo
The long awaited all-oral therapy for hepatitis C virus infection has officially been inaugurated by the registration of the hepatitis C nucleotide inhibitor sofosbuvir in a combination regimen with ribavirin. More recently, the oral array to treat hepatitis C has been enriched by the arrival of the NS5A inhibitors ledipasvir (also in a single formulation with sofosbuvir, Harvoni(®)) and daclatasvir; the protease inhibitor simeprevir, and the Viekirax(®)+Exviera™ regimen based on the ritonavir boosted protease inhibitor paritaprevir; the NS5A inhibitor ombitasvir, and the non-nucleoside inhibitor dasabuvir...
September 2015: Digestive and Liver Disease
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"